Transcript Highlights:

• Waste, fraud, and abuse thrive where welfare benefits are expansive and oversight is weak.
• Medicaid's expansion into non-medical services increased these risks.
• This creates perverse incentives that weaken program integrity and encourage welfare expansion.
• Expansion in other states has been characterized by low value spending and increased improper payments
• To address these issues, Texas should continue to resist further expansion of Medicaid, particularly

Committee: Senate Health & Human Services

Summary: The Senate Committee on Health and Human Services convened to discuss interim charges regarding fraud, waste, and abuse in Texas human services, particularly focusing on Medicaid and childcare programs. The meeting highlighted the importance of preventing misuse of taxpayer funds, with testimony from various stakeholders emphasizing the need for increased oversight and accountability in these programs. Key points included the alarming rise in healthcare fraud in other states, the necessity for Texas to enhance its fraud prevention measures, and the potential financial repercussions of failing to meet federal compliance standards. Several committee members expressed concerns about the impact of fraud on vulnerable populations, particularly those relying on Medicaid services. Testimonies from experts underscored the effectiveness of Texas's Office of Inspector General (OIG) in combating fraud, yet pointed out existing vulnerabilities, such as inconsistent enforcement and the need for better data sharing among agencies. The discussion also touched on the challenges faced by hospice care providers, with a significant increase in the number of hospices in Texas raising concerns about quality and oversight. The committee heard from various witnesses, including representatives from health plans and advocacy organizations, who provided insights into the complexities of managing Medicaid and the importance of maintaining program integrity. The meeting concluded with a commitment to further explore legislative solutions to enhance oversight and ensure that resources are directed to those in genuine need.

Transcript Highlights:

• Phil Christopherelli, with the Pharmaceutical Care Management Association, we are the nation's trade
• We negotiate rebates with pharmaceutical companies, we process drug claims, and we create networks of

Bills: SB25 , SB250 , HB22 , HB27 , HB33 , HB47 , HB233 , HB290 , HB308 , HB324 , HB382 , HB533 , HB559 , HB575 , HB980 , HB1157 , HB1207 , HB1236 , HCR45

Committee: Senate Finance

Transcript Highlights:

• as you said, this does advance it quite considerably because with, you know, especially with pharmaceuticals
• as you said, this does advance it quite considerably because with, you know, especially with pharmaceuticals

Bills: SB1786

Committees: House Artificial Intelligence & Innovation , House House Artificial Intelligence & Innovation Committee of Reference

Keywords: artificial intelligence, content verification, provenance data, transparency, digital content

Transcript Highlights:

• struggles with this bill, and one of the biggest ones is this does not provide any incentive for our pharmaceutical
• Pharma charges far too much for pharmaceuticals. Everybody knows that.

Summary: The Senate reconvened and handled several House messages and conference committee appointments before taking up a series of bills. It appointed conference committees on Senate Bill 2265 and House Bills 1454, 1448, and 1524. The chamber also adopted a Senate amendment to House Bill 1216, delaying its effective date for the copay accumulator prescription drug bill to January 1, 2026, with later renewal timing for non-PERS plans. House Bill 1216 then came up for final passage. Senators debated whether allowing copay accumulator programs to count manufacturer coupons toward deductibles would help patients with expensive drugs or unfairly shift costs to insurers and other policyholders. Supporters said it would help people afford life-saving medications and that the coupon payments go to pharmacies, not insurers; opponents argued it could raise premiums and create perverse incentives for drug pricing. The bill passed 29-18. The Senate also concurred in House amendments to Senate Bill 2160, which changes health insurance benefits under the Uniform Group Insurance Program to move from a grandfathered to a non-grandfathered plan, with supporters emphasizing added benefits and flexibility and opponents warning of higher costs and irreversible changes. That bill passed concurrence 33-14 and final passage 39-8. The Senate next concurred in House amendments to Senate Bill 2339, the wildfire mitigation bill, which requires utility mitigation plans to be updated every two years, incorporate national electric standards, and creates a rebuttable presumption of reasonable care if the plan is followed. The bill then passed final passage 46-1. The chamber also adopted conference committee reports and passed House Bill 1460 on adult foster care and monitoring devices, House Bill 1440 on cigar lounge tobacco use, and Senate Bill 2374 on insurance-related provisions including property insurance arbitration, managed repair programs, and surplus lines issues; SB 2374 also added a study on towing and recovery coverage. The session ended with announcements of upcoming conference committee meetings and adjournment until April 22, 2025.

Transcript Highlights:

• He will be medicated on pharmaceutical drugs for the rest of his life.
• Every pharmaceutical has milligram doses.

Bills: HB441 , HB445 , HB477 , HB441 , HB445

Committee: House Health

Keywords: speech-language pathology, licensure, clinical supervision, educational qualifications, healthcare assistant, hemp-derived cannabinoids, CBD, THC, delta-8, delta-9, delta-10, consumable hemp products, psychoactive cannabinoids, cannabinoid regulation, hemp licensing, ABC Board, Alcoholic Beverage Control Board, retail hemp sales, wholesale hemp distribution, hemp tax

Transcript Highlights:

• medical education. our medical establishment, they call it Rockefeller Medicine, all based on pharmaceuticals
• There's no pill, no pharmaceutical in the world that'll raise life expectancy by three years.

Committee: Senate Aging (Special) Committee

Keywords: health policy, lifespan, quality of life, community health, public testimony

Summary: The committee meeting was marked by discussions surrounding health policies aimed at enhancing the lifespan and quality of life for the community members. The chairperson initiated the session with personal reflections on the importance of extending not just the years of life but also the quality of those years, especially from the perspective of parents and grandparents. Members engaged in thoughtful dialogue regarding potential legislative measures that could address public health in a more holistic manner, emphasizing the need for community outreach and effective health education programs.

Transcript Highlights:

• And this bill in that way references an expansion of the humane tethering in a much broader sense to
• that are used in the Commonwealth, but in our life sciences industry, for the development of pharmaceuticals

Summary: The Senate opened with the Pledge of Allegiance, adopted a resolution congratulating Grant Marshall on earning Eagle Scout, and then passed two local/private bills to enactment: a sick leave bank for a Department of Correction employee and a measure waiving the Boston Police Department’s maximum age requirement for Luis Cabral. The chamber also received and journalized a communication from Senator Rush stating he would have voted yes on S. 3014 while away on Navy training. The Senate then took up several committee rule-suspension and extension orders. It approved extensions for the Joint Committee on Public Safety and Homeland Security on two late-filed matters until July 31, 2026, and approved two Health Care Financing extension orders, one extending 15 bills to March 31, 2026 and another extending six bills to May 1, 2026. Senators explained the delays as needed for hearings, stakeholder input, and mandated benefit reviews. The chamber also advanced local bills for Rutland recall elections, Boxford liquor licenses, Boston police age waivers, and Milton school construction timing, and adopted a resolution recognizing Endometriosis Awareness Month. A major portion of the session was devoted to H. 3014, the omnibus “Pets Act,” which combined provisions on animal welfare, pet shop sales, housing, insurance, and enforcement. Senators supporting the bill described it as banning the retail sale of dogs and cats from puppy mills, strengthening anti-cruelty enforcement, expanding access for animal control officers, limiting breed discrimination in housing and insurance, and protecting pet ownership in subsidized housing. Several amendments were debated: some were withdrawn or rejected, including proposals on renters’ insurance, nuisance barking, and property damage; others were adopted, including a compromise expanding protections for domestic animals, standards on animal welfare, and reporting/adoption requirements for research animals. The Ways and Means amendment was adopted as amended, and the bill was ordered to a third reading and then passed to be engrossed by roll call, with 38 members voting in the affirmative and none in the negative.

Transcript Highlights:

• And this bill in that way references an expansion of the humane tethering in a much broader sense to
• that are used in the Commonwealth, but in our life sciences industry, for the development of pharmaceuticals

Summary: The Senate opened with ceremonial items and several unanimous or voice votes, including adoption of a resolution congratulating Grant Marshall on earning Eagle Scout. It then enacted two bills: a sick leave bank for a Department of Correction employee and a measure directing the Boston Police Department to waive the maximum age requirement for a police officer applicant. The chamber also handled a communication from Senator Rush stating he would have voted yes on S. 3014 while on Navy training, and it printed that statement in the journal. The Senate next considered multiple local bills and committee reports, including third-reading and engrossment votes for a Rutland recall elections bill, a Boxford liquor license extension bill, and another Boston police age-waiver bill. It also adopted several extension orders for the Joint Committee on Public Safety and Homeland Security and the Committee on Health Care Financing, with senators explaining that some matters were late files or required additional stakeholder input, hearings, or coordination with larger bills. Most of these procedural motions were adopted by voice vote after brief debate. A major portion of the session focused on H. 2145, designating October 15 as Pregnancy and Infant Loss Awareness Day, which passed to be engrossed by roll call, 38-0. Senator Feeney gave an emotional floor speech describing the bill as a way to create space for awareness and support for families experiencing pregnancy loss. The Senate then adopted a resolution recognizing March 2026 as Endometriosis Awareness Month, with Senators Kennedy and others highlighting the need for greater awareness, diagnosis, and treatment of endometriosis. The chamber then took up the omnibus “Pets Act,” S. 3014, which combined several animal welfare measures. Senators Montigny, O’Connor, Todd, Rauch, and Payano spoke in support of provisions banning retail sales of dogs, cats, and rabbits from pet shops, strengthening animal cruelty enforcement, expanding protections for pets in housing, and prohibiting breed discrimination in certain housing and insurance contexts. Senator Keenan offered amendments on renter insurance, nuisance/quiet enjoyment, and property damage; one nuisance-related amendment was adopted, while the insurance and property-damage amendments were rejected. Senator Tarr’s amendment on research animals was adopted, as were amendments expanding animal welfare standards and, after negotiation, a compromise amendment broadening tethering protections to all domestic animals and directing related funds to the homeless animal fund. The Ways and Means amendment was then adopted as amended, the bill was ordered to a third reading, and the Senate began a roll-call vote on engrossment when the transcript ended.

Transcript Highlights:

• And in the 2025 session, our taxes were raised nearly 17%, mostly from the expansion on the sales tax
• utilize preferred drug status, or what we call our PDL, across our programs to manage the cost of pharmaceuticals

Summary: The Senate Health and Long-Term Care Committee heard testimony on several bills. SB 6159 would create a public hospital infrastructure account funded by a new annual coverage assessment on insurers and other businesses subject to the premium tax, and would allow public hospital districts and other public health entities to collaborate more freely and access capital financing for major construction or modernization projects. Senator Dhingra said the bill is intended to help public hospitals compete and modernize, especially amid federal Medicaid and ACA subsidy cuts. Supporters included UW Medicine, while hospital districts supported the general concept but said Section 2 could unintentionally narrow existing cooperative agreements with nonpublic entities. Health plans and insurers opposed the bill, arguing it would raise premiums, increase consolidation, and improperly sweep in property and casualty insurers and mutual companies; testimony also raised concerns about pass-through costs and retaliatory tax effects. The hearing on SB 6159 closed with 5 pro, 74 con, and 2 other sign-ins. The committee then heard SB 5845, which would modernize timely payment rules by requiring carriers and public employee plans to pay or deny all clean claims within 30 days, require prompt notice and a single request for additional information on incomplete claims, and impose interest or penalties for missed deadlines. Senator Slaughter said the bill would reduce uncertainty for providers and stabilize payments without increasing patient costs. Hospitals, physicians, and health systems strongly supported the measure, citing large volumes of late clean claims and examples of prolonged delays, including a Harborview claim that remained unpaid more than a year after billing. Health plans opposed the bill, saying the current 95% standard is workable, that they already meet high compliance rates, and that the bill could limit fraud, waste, and abuse review on high-dollar claims; they also sought more flexibility and additional time for responses. The hearing closed with 69 pro, 4 con, and 2 other sign-ins. The committee also heard SB 5916, which would prohibit health plans from disadvantaging non-opioid pain treatments relative to opioids in formularies and utilization management, and would require a Department of Health educational pamphlet on non-opioid alternatives. Senator Harris described the bill as a response to opioid deaths and a way to encourage safer pain treatment options. Patients, recovery advocates, and rare disease advocates testified in support, saying insurance barriers and step therapy often make non-opioid care harder to access and can push patients toward opioids. The Health Care Authority and an association of health plans opposed the bill, arguing it could reduce formulary flexibility, increase costs, and limit tools such as prior authorization and step therapy. The hearing closed with 8 pro, 1 con, and 2 other sign-ins. Finally, the committee heard SB 6102 and SB 6103, both sponsored by Senator Muzzall, and SB 6071. SB 6102 would align the ambulance transport quality assurance fee with federal rules after H.R. 1 barred new provider taxes, preserving the existing fee rate and adjusting the Medicaid add-on rate annually; the Washington Ambulance Association supported it, saying the program had improved wages and benefits for EMS workers. SB 6103 would make Medicaid payments for services provided by a rural emergency hospital subject to appropriation, creating a framework for East Adams Rural Health Care to convert to the new federal rural emergency hospital model; East Adams and the Washington State Hospital Association supported it as a way to preserve rural access. SB 6071 would shorten overpayment recovery timelines for all services to six months, or nine months for coordination-of-benefits cases, matching the shorter timelines already enacted for behavioral health services; providers and specialty associations supported the bill as a way to reduce destabilizing clawbacks, while the remaining testimony was still underway when the transcript ended.

Transcript Highlights:

• Um, as you may recall, the state benefits from a settlement fund with some of the pharmaceutical industry
• </c> fund with some of the pharmaceutical fund with some of the pharmaceutical industry<00:20:49.600>
• Next year you should expect an expansive bill around how we modernize and create workforce development
• Um, next year you should expect a Um, next year you should expect a expansive<01:50:21.440><c> bill</
• bill um around how we expansive bill um around how we modernize<01:50:24.040><c> and</c><01:50:24.400

Transcript Highlights:

• would probably have concerns with a we would probably have concerns with a full<01:30:32.040><c> expansion
• </c><01:30:32.679><c> of</c><01:30:32.920><c> power</c><01:30:33.280><c> purchase</c> full expansion
• of power purchase full expansion of power purchase agreements<01:30:34.960><c> um</c><01:30:35.800><c
• <03:48:00.000><c> industry</c><03:48:00.399><c> doing</c><03:48:00.800><c> drug</c> pharmaceutical industry
• doing drug pharmaceutical industry doing drug development<03:48:01.600><c> for</c><03:48:01.800><c>

Committee: House Science, Technology and Energy

Transcript Highlights:

• By way of background, members, as a result of litigation against numerous pharmaceutical manufacturers

Committee: Joint Joint Legislative Budget Committee

Transcript Highlights:

• encourage biosimilar use... ...to bring down cost and inject more competition into this system that pharmaceutical
• Currently, pharmaceutical companies often offer coupons to privately insured patients in order to provide
• they could lead to uncertainty about a patient's out-of-pocket cost from month to month, since pharmaceutical

Committee: Senate Health

Summary: The committee heard several health-related bills, beginning with SB 1124 on lung cancer screening awareness. The author and supporters said the bill would require CDPH signage about lung cancer screening eligibility at tobacco point-of-sale locations to address low awareness and low screening rates. Support came from medical students, physicians, and the California Academy of Family Physicians, while retailers raised concerns about sign size, retailer notification, and implementation. Committee members generally supported the bill and noted the need to work through those concerns. SB 1150 sought to require clearer patient notice when cancer cases are reported to the California Cancer Registry. The author described the bill as a response to inconsistent notification practices and privacy concerns, and the chair and other members shared personal stories about learning they or family members were in the registry without knowing it. Cancer registry and university stakeholders expressed appreciation for amendments but continued to have concerns or wanted more time to review the language. The bill was discussed as a patient-awareness measure rather than a change to reporting requirements. The committee also heard SB 1400 on Alameda Health System governance, SB 1094 on biosimilar substitution and health plan policies, SB 1314 on smoke shop regulation and nitrous oxide restrictions, and SB 1309 on eliminating cost-sharing for medically necessary follow-up after lung cancer screening. SB 1400 and SB 1314 drew support from local officials, labor, and public health advocates, with members emphasizing youth protection and local oversight. SB 1094 passed after extensive debate over pharmacist substitution authority and notification requirements, with a 6-0 vote and opposition from biotechnology and physician groups. SB 1309 also passed after members discussed the cost of follow-up care and the value of early detection, despite opposition from health plans over premium impacts; it received a 7-0 vote and was placed on call.

Transcript Highlights:

• encourage biosimilar use to bring down cost and inject more competition into this system that pharmaceutical
• Currently, pharmaceutical companies often offer coupons to privately insured patients in order to provide
• they could lead to uncertainty about a patient's out-of-pocket cost from month to month, since pharmaceutical

Summary: The committee heard several health-related bills, beginning with SB 1124, which would require the California Department of Public Health to create and post lung cancer screening eligibility signage at tobacco point-of-sale locations. The author and supporters said the bill is intended to raise awareness of a screening that many eligible Californians do not know exists; retailers raised concerns about signage size, distribution, and notice to stores. The bill was presented while the committee lacked quorum, so no vote was taken at that time. Members then heard SB 1150, which would require clearer patient notice when cancer cases are reported to the California Cancer Registry. The author and committee chair emphasized patient awareness and privacy, while registry and university stakeholders said they appreciated the amendments and would continue working on the language. SB 1400 followed, proposing changes to Alameda Health System governance to give Alameda County more flexibility and direct oversight; county and labor supporters said the current structure is too rigid for today’s health care environment, and no opposition was heard. The committee also heard SB 1094, which would expand substitution of biosimilars and generics to lower prescription drug costs. Supporters, including health plans and Sharp Health Care, said the bill would reduce premiums and out-of-pocket costs, while opponents from biotechnology and rheumatology groups raised concerns about pharmacist substitution, patient switching, and therapeutic equivalence. After quorum was established, SB 1094 passed 6-0 and was re-referred to Appropriations. The committee then heard SB 1314, which would create a statewide definition for smoke shops, impose a 600-foot buffer from sensitive sites, and restrict nitrous oxide sales; it drew broad support from local government, pediatric, and law enforcement groups and passed 6-0 on call. SB 1309, which would eliminate cost-sharing for medically appropriate lung cancer screening follow-up care, also passed 7-0 and was re-referred to Appropriations after testimony from clinicians, advocates, and insurers. Finally, SB 1199 was introduced to ban copay accumulators, with the sponsor and author arguing it would ensure patient assistance counts toward out-of-pocket maximums and improve medication access.

Transcript Highlights:

• encourage biosimilar use to bring down cost and inject more competition into this system that pharmaceutical
• Currently, pharmaceutical companies often offer coupons to privately insured patients in order to provide
• they could lead to uncertainty about a patient's out-of-pocket cost from month to month, since pharmaceutical

Committee: Senate Health

Transcript Highlights:

• Pharmaceutical for you, and for your specific DNA to cure whatever ails you.
• If you listen to the example about the benefits of creating a custom pharmaceutical based on your individual
• property through new material science that we can then license out to new battery technology and new pharmaceuticals

Committee: House Investments & Pensions Oversight Committee

Transcript Highlights:

• Half a blue pill, which I later came to find out looked exactly like a pharmaceutical-grade blue M30
• This was deceptively made to look exactly like a pharmaceutical-grade oxycodone pill, and it killed him
• They're dying because they've been deceptively sold a counterfeit pill that they think is a pharmaceutical-grade

Committee: Senate Senate Judiciary

Transcript Highlights:

• By way of background, members, as a result of litigation against numerous pharmaceutical manufacturers

Committee: Joint Joint Legislative Budget Committee

Summary: The Joint Legislative Budget Committee approved the minutes from its March 5, 2026 meeting and then entered executive session, where it approved a recommended settlement. After returning to open session, the committee took up the Attorney General’s opioid settlement expenditure plan. Staff explained that Arizona will receive opioid settlement funds over many years and that the FY 2026 budget appropriated $10 million for distribution to five counties. The plan would allocate $2 million each to Coconino, Mohave, Navajo, Pinal, and Yavapai counties. Members expressed support, noting the funds would continue programs they viewed as effective, and the committee gave the plan a favorable review. The committee also considered an Arizona Department of Administration request to transfer $7 million within the risk management revolving fund. Of that amount, $5 million would go to workers’ compensation losses and premiums to cover higher program costs, and $2 million would go to administrative expenses for higher-than-budgeted Attorney General contracted legal costs. Members described the transfer as a routine budget adjustment, and the committee approved it. Before adjournment, members asked staff about recent revenue trends, including April numbers and sports betting revenue. Staff said April data were still being analyzed and no definitive figures were available yet. On sports betting, staff said Arizona’s tax rate is in the range of other states but tends to be on the lower end. The committee then adjourned.

Transcript Highlights:

• is quite expensive, then oftentimes there are coupons or other help that is available through pharmaceutical

Committee: House Health and Welfare

Transcript Highlights:

• The problem in our pharmaceutical companies was that the cost of non-opiates was so much greater than
• The problem in in in our pharmaceutical<00:10:34.000><c> companies,</c><00:10:34.640><c> the</c><00:10
• :34.880><c> problem</c> pharmaceutical companies, the problem pharmaceutical companies, the problem was

Summary: The Senate Standing Committee on Health Services met with a quorum and first moved through administrative regulations without comment. The committee then heard Senate Bill 56, sponsored by Senator Gerald Neal, which would require Medicaid and its managed care entities to treat non-opioid pain medications on equal footing with opioid analgesics by prohibiting more restrictive coverage controls, prior authorization, or step therapy for non-opioids. Neal argued the bill would improve access to safer pain treatment options and reduce the risk of opioid use disorder, and Billy O'Brien of Young People in Recovery testified in support, describing personal experiences where non-opioid options were difficult to obtain despite a desire to avoid opioids. After discussion, the bill received a motion and second and passed the committee on a 10-0 vote. The committee then took up Senate Bill 72, sponsored by Senator Don Douglas and presented with Greg Chaffin of Alliance Defending Freedom. Douglas described the bill as a provider recruitment and retention measure intended to protect health care workers from being compelled to act against their conscience and to address workforce shortages and pressure in health care settings. He said the bill would protect individual beliefs while maintaining professionalism. A large number of witnesses then testified, and the chair limited public comments to two minutes each because of the number of speakers and the controversy surrounding the bill. Most public testimony opposed SB 72. Speakers including representatives of the Kentucky Council of Churches, a psychologist, an ordained minister and nurse, a nurse practitioner, and an ACLU policy strategist argued the bill was overly broad, could allow refusals of care by a wide range of health care workers, and could delay or deny treatment, especially for vulnerable patients and in rural or emergency settings. Several cited concerns about discrimination, patient safety, and the lack of adequate protections for patients. One witness recounted the death of an 18-year-old pregnant patient as an example of the harm that can result from delayed care. The transcript ends during additional testimony on SB 72, before any committee vote or final action on that bill is shown.